Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific B cells are a subset of B lymphocytes that recognize and respond to specific allergenic proteins. Their primary role in allergic disease is the production of immunoglobulin E (IgE) antibodies directed against components of allergens, which is central to the pathogenesis of immediate hypersensitivity reactions. They can be targeted by immunotherapies such as OIT.
Oral immunotherapy (OIT) modulates allergen-specific B cell activity, leading to reduced activation gene expression and altered antibody isotype production.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-specific B Cell (N/A).